This company has been marked as potentially delisted and may not be actively trading.

Apogee Therapeutics (APGE) Stock Forecast & Price Target

Get the Latest News and Ratings for APGE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Apogee Therapeutics and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

APGE Analyst Ratings Over Time

Type	Current Forecast 10/14/25 to 10/14/26	1 Month Ago 9/14/25 to 9/14/26	3 Months Ago 7/16/25 to 7/16/26	1 Year Ago 10/14/24 to 10/14/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	4 Buy rating(s)	7 Buy rating(s)
Hold	15 Hold rating(s)	15 Hold rating(s)	15 Hold rating(s)	1 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$126.77	$126.77	$121.25	$93.14
Forecasted Upside	-6.14% Downside	-6.14% Downside	-9.57% Downside	77.86% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

APGE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

APGE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Apogee Therapeutics Stock vs. The Competition

Type	Apogee Therapeutics	Healthcare Companies	Broader Market
Consensus Rating Score	2.16	2.32	2.53
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	-6.14% Downside	1,108.02% Upside	19.52% Upside
News Sentiment Rating	Neutral News See Recent APGE News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/13/2026	Truist Financial 3 of 5 stars	Danielle Brill 5 of 5 stars	Boost Target	Hold	$81.00 ➝ $135.00	+0.34%
8/12/2026	BTIG Research 3 of 5 stars	Julian Harrison 5 of 5 stars	Downgrade	Buy ➝ Neutral
7/17/2026	Weiss Ratings 3 of 5 stars		Reiterated Rating	Sell (D-)
6/24/2026	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Joseph Catanzaro Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Outperform ➝ Neutral	$110.00 ➝ $135.00	+1.60%
6/24/2026	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Akash Tewari Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Buy ➝ Hold	$133.00 ➝ $135.00	+1.52%
6/23/2026	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Tyler Van Buren Subscribe to MarketBeat All Access to unlock analyst rankings	Downgrade	Buy ➝ Hold
6/23/2026	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Seamus Fernandez Subscribe to MarketBeat All Access to unlock analyst rankings	Downgrade	Buy ➝ Neutral
6/23/2026	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Michael Yee Subscribe to MarketBeat All Access to unlock analyst rankings	Downgrade	Buy ➝ Neutral	$100.00 ➝ $135.11	+1.93%
6/23/2026	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Geoff Meacham Subscribe to MarketBeat All Access to unlock analyst rankings	Downgrade	Buy ➝ Neutral	$125.00 ➝ $135.00	+1.69%
6/22/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access to unlock brokerage rankings	David Hoang Subscribe to MarketBeat All Access to unlock analyst rankings	Downgrade	Buy ➝ Hold	$116.00 ➝ $135.00	+1.85%
Get the Latest News and Ratings for APGE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Apogee Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
6/22/2026	Craig Hallum Subscribe to MarketBeat All Access to unlock brokerage rankings		Set Target	Buy ➝ Hold	$135.11	+1.89%
6/22/2026	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	David Nierengarten Subscribe to MarketBeat All Access to unlock analyst rankings	Downgrade	Outperform ➝ Neutral	$135.00	+1.81%
6/22/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Edward Nash Subscribe to MarketBeat All Access to unlock analyst rankings	Downgrade	Buy ➝ Hold	$130.00 ➝ $135.11	+1.86%
6/8/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Brian Abrahams Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Sector Perform	$82.00 ➝ $97.00	+11.60%
5/28/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings		Set Target		$89.00	+13.64%
5/1/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access to unlock brokerage rankings	Qize Ding Subscribe to MarketBeat All Access to unlock analyst rankings	Initiated Coverage	Buy	$140.00	+68.90%
2/2/2026	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Akash Tewari Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Buy	$95.00	+43.81%
1/7/2026	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Andy Chen Subscribe to MarketBeat All Access to unlock analyst rankings	Initiated Coverage	Peer Perform
12/16/2025	Stephens Subscribe to MarketBeat All Access to unlock brokerage rankings	Sudan Loganathan Subscribe to MarketBeat All Access to unlock analyst rankings	Initiated Coverage	Overweight	$95.00	+27.04%
8/28/2025	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Tim Anderson Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Buy	$78.00 ➝ $87.00	+135.26%
8/14/2025	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings		Downgrade	Strong-Buy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:03 PM ET.

APGE Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Apogee Therapeutics is $126.77, with a high forecast of $160.00 and a low forecast of $89.00.

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Apogee Therapeutics in the last year. There is currently 1 sell rating, 15 hold ratings, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" APGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in APGE, but not buy additional shares or sell existing shares.

According to analysts, Apogee Therapeutics's stock has a predicted downside of -6.14% based on their 12-month stock forecasts.

Over the previous 90 days, Apogee Therapeutics's stock had 1 downgrade by analysts.

Apogee Therapeutics has been rated by research analysts at BTIG Research, Truist Financial, and Weiss Ratings in the past 90 days.

Analysts like Apogee Therapeutics less than other "healthcare" companies. The consensus rating score for Apogee Therapeutics is 2.16 while the average consensus rating score for "healthcare" companies is 2.32. Learn more on how APGE compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Apogee Therapeutics Recommendations

MarketBeat monitors more than a dozen sources for Apogee Therapeutics analyst ratings, with the most recent rating issued on 8/13/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.